Luke Miels

Stories

FDA approves first-of-its-kind hepatitis B drug from GSK and Ionis

Leading GSK's push to launch new medicines ahead of HIV patent expirations

The Food and Drug Administration approved Hibsago on October 20 for chronic hepatitis B, giving some patients a way to stop daily antiviral pills. In two late-stage trials, 19% of patients who took it had no detectable virus 24 weeks after ending all treatment, against less than 1% for standard care.

Updated 6 days ago

GSK buys cancer drugmaker Nuvalent for $10.6 billion

Money Moves

Deal closed September 2026; leading GSK's push into lung cancer

GSK closed its $10.6 billion purchase of Nuvalent in September, netting out to about $9.4 billion in cash. Both lung cancer drugs central to the deal were still under FDA review at closing; a ruling on neladalkib is due November 27.

Updated Oct 8

The race to protect 27 million Americans from accidental food allergen exposure

Money Moves

Assumed role January 1, 2026

For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.

Updated May 22

Notable Quotes

"Today's deal completion accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development. There is a clear need for these medicines in defined patient populations, consistent with our approach of acquiring validated assets that aim to improve standard of care."

from GSK buys cancer drugmaker Nuvalent for $10.6 billion · Updated Oct 8